UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                        to    

Commission File Number: 001-37725

 

ViewRay, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

42-1777485

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

2 Thermo Fisher Way

Oakwood Village, OH

 

44146

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (440) 703-3210

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01

 

VRAY

 

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 Large accelerated filer

 

☐

  

Accelerated filer

 

☒

 

 

 

 

 

 

 

Non-accelerated filer

 

☐ 

  

Smaller reporting company

 

☒

 

 

 

 

 

 

 

Emerging growth company

 

☒

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

As of November 1, 2019, the registrant had 99,406,356 shares of common stock, $0.01 par value per share, outstanding.

 

 

 

 

VIEWRAY, INC.

FORM 10-Q

TABLE OF CONTENTS

 

 

 

 

Page

 

 

 

 

PART I.

FINANCIAL INFORMATION

 

 

 

 

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

3

 

 

 

 

Item 1.

Unaudited Condensed Consolidated Financial Statements

 

4

 

 

 

 

 

Condensed Consolidated Balance Sheets

 

4

 

 

 

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

 

5

 

 

 

 

 

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity

 

6

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows

 

8

 

 

 

 

 

Notes to the Condensed Consolidated Financial Statements

 

9

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

23

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

33

 

 

 

 

Item 4.

Controls and Procedures

 

33

 

 

 

 

PART II.

OTHER INFORMATION

 

 

 

 

 

 

Item 1.

Legal Proceedings

 

34

 

 

 

 

Item 1A.

Risk Factors

 

34

 

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

34

 

 

 

 

Item 3.

Defaults Upon Senior Securities

 

34

 

 

 

 

Item 4.

Mine Safety Disclosures

 

34

 

 

 

 

Item 5.

Other Information

 

34

 

 

 

 

Item 6.

Exhibits

 

35

 

 

 

 

 

Signatures

 

36

 


2

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or this Report, contains forward-looking statements, including, without limitation, in the sections captioned “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere. Any and all statements contained in this Report that are not statements of historical fact may be deemed forward-looking statements. Terms such as “will”, “may,” “might,” “would,” “should,” “could,” “project,” “estimate,” “pro forma,” “predict,” “potential,” “strategy,” “anticipate,” “attempt,” “develop,” “plan,” “help,” “believe,” “continue,” “intend,” “expect,” “future” and terms of similar import (including the negative of any of the foregoing) may be intended to identify forward-looking statements. However, not all forward-looking statements may contain one or more of these identifying terms. Forward-looking statements in this Report may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) our future financial performance, including any such statement contained in a discussion and analysis of financial condition by management or in the results of operations included pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above.

The forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon our current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which we have no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation:

 

•

market acceptance of magnetic resonance imaging (“MRI”) guided radiation therapy;

 

•

the benefits of MR Image-Guided radiation therapy;

 

•

our ability to successfully sell and market MRIdian® in our existing and expanded geographies;

 

•

the performance of MRIdian in clinical settings;

 

•

competition from existing technologies or products or new technologies and products that may emerge;

 

•

the pricing and reimbursement of MR Image-Guided radiation therapy;

 

•

the implementation of our business model and strategic plans for our business and MRIdian;

 

•

the scope of protection we are able to establish and maintain for intellectual property rights covering MRIdian;

 

•

our ability to obtain regulatory approval in targeted markets for MRIdian;

 

•

our ability to procure materials and components in connection with the manufacture and installation of MRIdian;

 

•

estimates of our future revenue, expenses, capital requirements and our need for additional financing;

 

•

our financial performance;

 

•

our expectations related to the MRIdian linear accelerator technology, or MRIdian Linac;

 

•

developments relating to our competitors and the healthcare industry; and

 

•

other risks and uncertainties, including those listed under the section titled “Risk Factors.”

Any forward-looking statements in this Report reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item 1A, titled “Risk Factors” and discussed elsewhere in this Report, and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018. Given these uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update the forward-looking statements contained in this Report to reflect any new information or future events or circumstances or otherwise, except as required by law.

This Report also contains estimates, projections and other information concerning our industry, our business, and the markets for certain devices, including data regarding the estimated size of those markets. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

3

 

PART I—FINANCIAL INFORMATION

 

Item 1. Unaudited Condensed Consolidated Financial Statements

VIEWRAY, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

 

 

 

September 30,

2019

 

 

December 31,

2018

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

90,756

 

 

$

167,432

 

Accounts receivable

 

 

33,301

 

 

 

36,867

 

Inventory

 

 

59,622

 

 

 

49,462

 

Deposits on purchased inventory

 

 

4,883

 

 

 

8,142

 

Deferred cost of revenue

 

 

3,056

 

 

 

9,736

 

Prepaid expenses and other current assets

 

 

4,672

 

 

 

6,045

 

Total current assets

 

 

196,290

 

 

 

277,684

 

Property and equipment, net

 

 

23,437

 

 

 

13,958

 

Restricted cash

 

 

1,442

 

 

 

1,933

 

Intangible assets, net

 

 

57

 

 

 

—

 

Right-of-use assets

 

 

12,254

 

 

 

—

 

Other assets

 

 

2,255

 

 

 

1,395

 

TOTAL ASSETS

 

$

235,735

 

 

$

294,970

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

11,648

 

 

$

10,207

 

Accrued liabilities

 

 

18,835

 

 

 

9,983

 

Customer deposits

 

 

10,746

 

 

 

19,968

 

Operating lease liability, current

 

 

2,139

 

 

 

—

 

Deferred revenue, current

 

 

9,644

 

 

 

13,731

 

Total current liabilities

 

 

53,012

 

 

 

53,889

 

Deferred revenue, net of current portion

 

 

4,516

 

 

 

5,744

 

Long-term debt

 

 

55,489

 

 

 

55,364

 

Warrant liabilities

 

 

3,194

 

 

 

11,844

 

Operating lease liability, noncurrent

 

 

11,067

 

 

 

—

 

Other long-term liabilities

 

 

562

 

 

 

820

 

TOTAL LIABILITIES

 

 

127,840

 

 

 

127,661

 

Commitments and contingencies (Note 6)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Convertible preferred stock, par value of $0.01 per share; 10,000,000 shares authorized

   at September 30, 2019 and December 31, 2018; no shares issued and outstanding

   at September 30, 2019 and December 31, 2018

 

 

—

 

 

 

—

 

Common stock, par value of $0.01 per share; 300,000,000 shares authorized at

   September 30, 2019 and December 31, 2018; 99,405,805 and 96,332,023 shares

   issued and outstanding at September 30, 2019 and December 31, 2018

 

 

984

 

 

 

952

 

Additional paid-in capital

 

 

590,878

 

 

 

565,334

 

Accumulated deficit

 

 

(483,967

)

 

 

(398,977

)

TOTAL STOCKHOLDERS’ EQUITY

 

 

107,895

 

 

 

167,309

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

235,735

 

 

$

294,970

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

 

VIEWRAY, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)

(Unaudited)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

18,696

 

 

$

16,492

 

 

$

65,475

 

 

$

57,237

 

Service

 

 

2,048

 

 

 

1,056

 

 

 

5,482

 

 

 

2,706

 

Distribution rights

 

 

118

 

 

 

118

 

 

 

356

 

 

 

356

 

Total revenue

 

 

20,862

 

 

 

17,666

 

 

 

71,313

 

 

 

60,299

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

 

18,521

 

 

 

15,199

 

 

 

63,368

 

 

 

49,564

 

Service

 

 

1,767

 

 

 

2,103

 

 

 

9,489

 

 

 

4,732

 

Total cost of revenue

 

 

20,288

 

 

 

17,302

 

 

 

72,857

 

 

 

54,296

 

Gross margin

 

 

574

 

 

 

364

 

 

 

(1,544

)

 

 

6,003

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

5,641

 

 

 

4,347

 

 

 

17,135

 

 

 

12,506

 

Selling and marketing

 

 

7,297

 

 

 

3,384

 

 

 

19,845

 

 

 

10,024

 

General and administrative

 

 

19,381

 

 

 

16,721

 

 

 

49,888

 

 

 

37,070

 

Total operating expenses

 

 

32,319

 

 

 

24,452

 

 

 

86,868

 

 

 

59,600

 

Loss from operations

 

 

(31,745

)

 

 

(24,088

)

 

 

(88,412

)

 

 

(53,597

)

Interest income

 

 

484

 

 

 

2

 

 

 

1,391

 

 

 

6

 

Interest expense

 

 

(1,069

)

 

 

(1,974

)

 

 

(2,902

)

 

 

(5,758

)

Other income (expense), net

 

 

11,499

 

 

 

(6,792

)

 

 

4,933

 

 

 

(307

)

Loss before provision for income taxes

 

$

(20,831

)

 

$

(32,852

)

 

$

(84,990

)

 

$

(59,656

)

Provision for income taxes

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Net loss and comprehensive loss

 

$

(20,831

)

 

$

(32,852

)

 

$

(84,990

)

 

$

(59,656

)

Amortization of beneficial conversion feature related to Series A convertible preferred stock

 

$

—

 

 

$

—

 

 

$

—

 

 

$

(2,728

)

Net loss attributable to common stockholders, basic and diluted

 

$

(20,831

)

 

$

(32,852

)

 

$

(84,990

)

 

$

(62,384

)

Net loss per share, basic and diluted

 

$

(0.21

)

 

$

(0.39

)

 

$

(0.87

)

 

$

(0.82

)

Weighted-average common shares used to compute net loss per

   share attributable to common stockholders, basic and diluted

 

 

99,039,789

 

 

 

84,920,996

 

 

 

97,763,964

 

 

 

76,185,346

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements

 

5

 

VIEWRAY, INC.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except share and per share data)

(Unaudited)

 

 

 

 

Convertible Preferred Stock

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Accumulated

Deficit

 

 

Total

Stockholders’

Equity

 

Three Months Ended September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2019

 

 

—

 

 

$

—

 

 

$

—

 

 

 

98,259,203

 

 

$

973

 

 

$

585,080

 

 

$

(463,136

)

 

$

122,917

 

Issuance of common stock from option exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

517,624

 

 

 

5

 

 

 

1,433

 

 

 

—

 

 

 

1,438

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,910

 

 

 

—

 

 

 

4,910

 

Issuance of common stock from releases of restricted stock units

 

 

—

 

 

 

—

 

 

 

—

 

 

 

335,863

 

 

 

3

 

 

 

(3

)

 

 

—

 

 

 

—

 

Tax withholding paid on behalf of employees for stock-based awards

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,410

)

 

 

—

 

 

 

(2,410

)

Issuance of common stock from warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

293,115

 

 

 

3

 

 

 

(3

)

 

 

—

 

 

 

—

 

Reclassification of warrant liability to additional paid-in capital upon warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,871

 

 

 

—

 

 

 

1,871

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(20,831

)

 

 

(20,831

)

Balance at September 30, 2019

 

 

—

 

 

$

—

 

 

$

—

 

 

 

99,405,805

 

 

$

984

 

 

$

590,878

 

 

$

(483,967

)

 

$

107,895

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2018

 

 

—

 

 

$

—

 

 

$

—

 

 

 

96,332,023

 

 

$

952

 

 

$

565,334

 

 

$

(398,977

)

 

$

167,309

 

Issuance of common stock from option exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

2,219,251

 

 

 

23

 

 

 

9,618

 

 

 

—

 

 

 

9,641

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

14,369

 

 

 

—

 

 

 

14,369

 

Issuance of common stock from releases of restricted stock units

 

 

—

 

 

 

—

 

 

 

—

 

 

 

390,332

 

 

 

4

 

 

 

(4

)

 

 

—

 

 

 

—

 

Tax withholding paid on behalf of employees for stock-based awards

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(2,410

)

 

 

—

 

 

 

(2,410

)

Issuance of common stock from warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

464,199

 

 

 

5

 

 

 

(5

)

 

 

—

 

 

 

—

 

Reclassification of warrant liability to additional paid-in capital upon warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

3,976

 

 

 

—

 

 

 

3,976

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(84,990

)

 

 

(84,990

)

Balance at September 30, 2019

 

 

—

 

 

$

—

 

 

$

—

 

 

 

99,405,805

 

 

$

984

 

 

$

590,878

 

 

$

(483,967

)

 

$

107,895

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 


6

 

VIEWRAY, INC.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except share and per share data)

(Unaudited)

 

 

 

 

Convertible Preferred Stock

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Accumulated

Deficit

 

 

Total

Stockholders’

Equity

 

Three Months Ended September 30, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at June 30, 2018

 

 

—

 

 

$

—

 

 

$

—

 

 

 

75,188,832

 

 

$

741

 

 

$

386,610

 

 

$

(349,385

)

 

$

37,966

 

Issuance of common stock from option exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,210,169

 

 

 

12

 

 

 

2,844

 

 

 

—

 

 

 

2,856

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

7,179

 

 

 

—

 

 

 

7,179

 

Issuance of common stock from releases of restricted stock units

 

 

—

 

 

 

—

 

 

 

—

 

 

 

26,388

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock from warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

121,834

 

 

 

1

 

 

 

(1

)

 

 

—

 

 

 

—

 

Issuance of common stock from at-the-market offering (net of offering cost of $10,631)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

18,648,649

 

 

 

187

 

 

 

161,682

 

 

 

—

 

 

 

161,869

 

Reclassification of warrant liability to additional paid-in capital upon warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

342

 

 

 

—

 

 

 

342

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(32,852

)

 

 

(32,852

)

Balance at September 30, 2018

 

 

—

 

 

$

—

 

 

$

—

 

 

 

95,195,872

 

 

$

941

 

 

$

558,656

 

 

$

(382,237

)

 

$

177,360

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2017

 

 

—

 

 

$

—

 

 

$

—

 

 

 

67,653,974

 

 

$

666

 

 

$

321,174

 

 

$

(319,853

)

 

$

1,987

 

Issuance of common stock from option exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

1,607,108

 

 

 

16

 

 

 

3,555

 

 

 

—

 

 

 

3,571

 

Stock-based compensation

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

10,052

 

 

 

—

 

 

 

10,052

 

Issuance of common stock from releases of restricted stock units

 

 

—

 

 

 

—

 

 

 

—

 

 

 

38,856

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Issuance of common stock from warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

123,607

 

 

 

1

 

 

 

(1

)

 

 

—

 

 

 

—

 

Issuance of common stock upon direct registered offering (net of offering cost of $177)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

4,090,000

 

 

 

41

 

 

 

30,052

 

 

 

—

 

 

 

30,093

 

Issuance of preferred Series A stock upon direct registered offering

 

 

3,000,581

 

 

 

30

 

 

 

22,177

 

 

 

—

 

 

 

—

 

 

 

2,728

 

 

 

(2,728

)

 

 

22,207

 

Issuance of common stock warrants in connection with direct registered offering

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

6,623

 

 

 

—

 

 

 

6,623

 

Conversion of Series A preferred stock into common stock

 

 

(3,000,581

)

 

 

(30

)

 

 

(22,177

)

 

 

3,000,581

 

 

 

30

 

 

 

22,177

 

 

 

—

 

 

 

—

 

Issuance of common stock from at-the-market offering (net of offering cost of $10,637)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

18,681,746

 

 

 

187

 

 

 

161,954

 

 

 

—

 

 

 

162,141

 

Reclassification of warrant liability to additional paid-in capital upon warrant exercises

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

342

 

 

 

—

 

 

 

342

 

Net loss

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(59,656

)

 

 

(59,656

)

Balance at September 30, 2018

 

 

—

 

 

$

—

 

 

$

—

 

 

 

95,195,872

 

 

$

941

 

 

$

558,656

 

 

$

(382,237

)

 

$

177,360

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

 

VIEWRAY, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(84,990

)

 

$

(59,656

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

3,156

 

 

 

2,561

 

Stock-based compensation

 

 

14,369

 

 

 

10,052

 

Accretion on asset retirement obligation

 

 

22

 

 

 

26

 

Change in fair value of warrant liabilities

 

 

(4,674

)

 

 

(116

)

Loss on disposal of property and equipment

 

 

—

 

 

 

1

 

Amortization of debt discount and interest accrual

 

 

472

 

 

 

2,703

 

Product upgrade reserve

 

 

4,431

 

 

 

—

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

3,566

 

 

 

(2,351

)

Inventory

 

 

(10,514

)

 

 

(22,412

)

Deposits on purchased inventory

 

 

3,259

 

 

 

1,478

 

Deferred cost of revenue

 

 

1,951

 

 

 

2,327

 

Prepaid expenses and other assets

 

 

852

 

 

 

(2,262

)

Accounts payable

 

 

1,231

 

 

 

(4,067

)

Accrued expenses and other long-term liabilities

 

 

4,774

 

 

 

6,732

 

Customer deposits and deferred revenue

 

 

(14,537

)

 

 

(12,445

)

Net cash used in operating activities

 

 

(76,632

)

 

 

(77,429

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(7,541

)

 

 

(2,814

)

Purchase of intangible asset

 

 

(57

)

 

 

—

 

Net cash used in investing activities

 

 

(7,598

)

 

 

(2,814

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from common stock public offering, gross

 

 

—

 

 

 

172,500

 

Payment of offering costs related to common stock public offering

 

 

—

 

 

 

(10,631

)

Proceeds from at-the-market offering of common stock, gross

 

 

—

 

 

 

278

 

Payment of offering costs related to at-the-market offering of common stock

 

 

—

 

 

 

(6

)

Proceeds from direct registered offering, gross

 

 

—

 

 

 

59,100

 

Payment of offering costs related to direct registered offering

 

 

—

 

 

 

(177

)

Payment of debt issuance cost

 

 

(168

)

 

 

—

 

Proceeds from the exercise of stock options

 

 

9,641

 

 

 

3,571

 

Payments for taxes related to net share settlement of equity awards

 

 

(2,410

)

 

 

—

 

Net cash provided by financing activities

 

 

7,063

 

 

 

224,635

 

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

(77,167

)

 

 

144,392

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH — BEGINNING OF PERIOD

 

 

169,365

 

 

 

58,532

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH — END OF PERIOD

 

$

92,198

 

 

$

202,924

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid for interest

 

$

2,879

 

 

$

3,055

 

Cash paid for taxes

 

$

7

 

 

$

—

 

SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Fair value of common stock warrants reclassified from liability to additional paid-in capital upon exercise

 

$

3,976

 

 

$

342

 

Right-of-use assets obtained in exchange for new operating lease liabilities

 

$

1,647

 

 

$

—

 

Transfer of property and equipment from inventory and deferred cost of revenue

 

$

4,446

 

 

$

1,700

 

Purchases of property and equipment in accounts payable and accrued liabilities

 

$

491

 

 

$

129

 

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

VIEWRAY, INC.

8

 

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.Background and Organization

ViewRay, Inc., or ViewRay or the Company, and its wholly-owned subsidiary ViewRay Technologies, Inc., designs, manufactures and markets MRIdian, an MR Image-Guided radiation therapy system to simultaneously image and treat cancer patients.

Since inception, ViewRay Technologies, Inc. has devoted substantially all of its efforts towards research and development, initial selling and marketing activities, raising capital and the manufacturing, shipment and installation of MRIdian systems. In May 2012, ViewRay Technologies, Inc. was granted clearance from the U.S. Food and Drug Administration, or FDA, to sell MRIdian with Cobalt-60. In November 2013, ViewRay Technologies, Inc. received its first clinical acceptance of a MRIdian with Cobalt-60 at a customer site, and the first patient was treated with that system in January 2014. ViewRay Technologies, Inc. has had the right to affix the CE mark to MRIdian with Cobalt-60 in the European Economic Area since November 2014. In September 2016, the Company received the rights to affix the Conformité Européene, or CE, mark to MRIdian Linac, and in February 2017, the Company received 510(k) clearance from the FDA to market MRIdian Linac.

The Company’s condensed consolidated financial statements have been prepared on the basis of the Company continuing as a going concern. The Company’s principal sources of liquidity are cash flows from public and private offerings and available borrowings under its term loan agreement, as well as cash receipts from its sales of MRIdian systems. These have historically been sufficient to meet working capital needs, capital expenditures, operating expenses, and debt service obligations. During the nine months ended September 30, 2019, the Company incurred a net loss of $85.0 million and used cash in operating activities of $76.6 million. The Company believes that its existing cash balance of $90.8 million as of September 30, 2019, together with anticipated cash proceeds from sales of MRIdian systems will be sufficient to provide liquidity to fund its operations for at least the next 12 months.

2.

Summary of Significant Accounting Policies

Basis of Presentation

The condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States, or U.S. GAAP, and pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. The condensed consolidated financial statements include the accounts of ViewRay, Inc. and its wholly-owned subsidiary, ViewRay Technologies, Inc. All inter-company accounts and transactions have been eliminated in consolidation.

In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s unaudited condensed consolidated financial statements, have been included. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019 or any future period. These unaudited condensed consolidated financial statements and their notes should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Effective January 1, 2019, the Company adopted the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 842, or Topic 842, Leases, by using a modified retrospective transition approach. The adoption of Topic 842 had no impact on the Company’s prior period financial statements. Refer to Note 6, Commitments and Contingencies for further information and related disclosures.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements are disclosed in the notes to consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 filed with the SEC on March 15, 2019, and have not changed significantly since that filing, except for the January 1, 2019 adoption of the new accounting guidance Topic 842, Leases, and the second quarter 2019 change in the recognition of certain revenue resulting from changes in facts and circumstances. Refer to the Recently Adopted Accounting Pronouncements below and to Note 6, Commitments and Contingencies, and Note 7, Revenue, for further information and related disclosures.

9

 

Recent Accounting Pronouncements

In August 2018, the FASB issued Accounting Standards Update, or ASU, No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework- Changes to the Disclosure Requirements for Fair Value Measurement, to modify the disclosure requirements on fair value measurements in Topic 820. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019, and interim periods therein. The Company is allowed to early adopt either the entire standard or only the provisions that eliminate or modify the requirements of Topic 820. The Company is evaluating the impact of this update on its consolidated financial statements and related disclosures.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases, and issued subsequent amendments to the initial guidance in September 2017 within ASU 2017-13, in January 2018 within ASU 2018-01, in July 2018 within ASU 2018-10 and ASU 2018-11, and in March 2019 within ASU 2019-01 (collectively, Topic 842). Topic 842 supersedes Topic 840, Leases, and requires lessees to recognize on their balance sheets all leases, with the exception of short-term leases, as a right-of-use asset and a corresponding lease liability measured at the present value of the lease payments. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement. The new standard requires expanded disclosures regarding leasing arrangements. Effective January 1, 2019, the Company adopted Topic 842 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. There was no cumulative-effect adjustment recorded to retained deficit upon adoption.

Topic 842 provides several optional practical expedients in transition. The Company elected to use the package of practical expedients permitted under the transition guidance, which allows the Company not to reassess its prior conclusions about lease identification, lease classification and initial direct costs for any leases that existed prior to January 1, 2019. The Company did not elect to use the other practical expedients provided.

Upon adoption, the Company recognized the right-of-use assets and operating lease liabilities totaling approximately $11.9 million and $12.6 million, respectively, to reflect the present value of remaining lease payments under existing lease arrangements with no impact to the opening balance of retained deficit as a result of adoption. The difference between the leased assets and lease liabilities represents the existing deferred rent liabilities balance, resulting from historical straight-lining of operating leases, which was effectively reclassified upon adoption to reduce the measurement of the leased assets.

In determining the present value of lease payments, the Company uses the rate implicit in the lease or when such rate is not readily available, we utilize our incremental borrowing rate based on the information available at the lease commencement date. Lease expense is recognized on a straight-line basis over the expected lease term. In determining the expected lease term, the Company may include options to extend or terminate the lease when it is reasonably certain that it will exercise any such option. For more information on the impact of adoption and the disclosures required by the new standard, refer to Note 6, Commitments and Contingencies.

In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company adopted ASU 2018-07 on January 1, 2019, and the adoption did not have a material impact on its condensed consolidated financial statements and related disclosures.

 

3.

Balance Sheet Components

Property and Equipment, Net

Property and equipment consisted of the following (in thousands): 

 

 

September 30, 2019

 

 

December 31,

2018

 

Prototype

 

$

12,512

 

 

$

12,425

 

Machinery and equipment

 

 

15,588

 

 

 

12,654

 

Leasehold improvements

 

 

5,055

 

 

 

4,600

 

Furniture and fixtures

 

 

998

 

 

 

636

 

Software

 

 

1,389

 

 

 

1,250

 

Construction in progress

 

 

8,806

 

 

 

148

 

Property and equipment, gross

 

 

44,348

 

 

 

31,713

 

Less: accumulated depreciation and amortization

 

 

(20,911

)

 

 

(17,755

)

Property and equipment, net

 

$

23,437

 

 

$

13,958

 

 

10

 

Depreciation and amortization expense related to property and equipment were $1.2 million and $0.9 million during the three months ended September 30, 2019 and 2018, and $3.2 million and $2.5 million during the nine months ended September 30, 2019 and 2018, respectively.

Intangible Assets

In September 2019, the Company entered into a licensing agreement (the “License”) with VU University Medical Center, or VUmc, whereby VUmc granted the Company a worldwide exclusive license to developed strategies for fast stereotactic MR-guided adaptive radiation therapy for $57 thousand. The License is amortized on a straight-line basis over ten years. During the three and nine months ended September 30, 2019 and 2018, there was no intangible assets amortization expense.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

September 30, 2019

 

 

December 31,

2018

 

Accrued payroll and related benefits

 

$

7,094

 

 

$

5,047

 

Accrued accounts payable

 

 

2,683

 

 

 

3,626

 

Payroll withholding tax, sales and other tax payable

 

 

3,378

 

 

 

782

 

Accrued legal, accounting and professional fees

 

 

375

 

 

 

360

 

Product upgrade reserve

 

 

3,794

 

 

 

—

 

Other

 

 

1,511

 

 

 

168

 

Total accrued liabilities

 

$

18,835

 

 

$

9,983

 

Deferred Revenue

Deferred revenue consisted of the following (in thousands):

 

 

 

September 30, 2019

 

 

December 31,

2018

 

Deferred revenue:

 

 

 

 

 

 

 

 

Product

 

$

3,654

 

 

$

9,623

 

Service

 

 

7,991

 

 

 

6,981

 

Distribution rights

 

 

2,515

 

 

 

2,871

 

Total deferred revenue

 

 

14,160

 

 

 

19,475

 

Less: current portion of deferred revenue

 

 

(9,644

)

 

 

(13,731

)

Noncurrent portion of deferred revenue

 

$

4,516

 

 

$

5,744

 

 

Other Long-Term Liabilities

 

 

 

September 30, 2019

 

 

December 31,

2018

 

Accrued interest, noncurrent portion

 

$

347

 

 

$

—

 

Deferred rent, noncurrent portion

 

 

—

 

 

 

628

 

Other

 

 

215

 

 

 

192

 

Total other-long term liabilities

 

$

562

 

 

$

820

 

 


11

 

4.

Fair Value of Financial Instruments

Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The assets’ or liabilities’ fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The Company’s financial instruments that are carried at fair value mainly consist of Level 1 assets and Level 3 liabilities. Level 1 assets include highly liquid bank deposits and money market funds, which were not material at September 30, 2019 and December 31, 2018. Level 3 liabilities that are measured on a recurring basis relate to the 2017 and 2016 Placement Warrants, as described in Note 9. Placement warrant liabilities are valued using the Black-Scholes option-pricing model. Generally, increases (decreases) in the fair value of the underlying stock, volatility and estimated term would result in a directionally similar impact to the fair value of the warrants (see Note 9).

The gains and losses from re-measurement of Level 3 financial liabilities are recorded as part of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. During the three and nine months ended September 30, 2019, the Company recorded a gain of $13.5 million and a gain of $8.6 million, respectively, related to the change in fair value of the 2017 and 2016 Placement Warrants. During the three and nine months ended September 30, 2018, the Company recorded a loss of $6.7 million and a gain of $0.4 million, respectively, related to the change in fair value of the 2017 and 2016 Placement Warrants. There were no transfers between Level 1, Level 2 and Level 3 in any periods presented.

The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands): 

 

 

 

At September 30, 2019

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

2017 Placement Warrants Liability

 

$

—

 

 

$

—

 

 

$

2,408

 

 

$

2,408

 

2016 Placement Warrants Liability

 

 

—

 

 

 

—

 

 

 

786

 

 

 

786

 

    Total

 

$

—

 

 

$

—

 

 

$

3,194

 

 

$

3,194

 

 

 

 

At December 31, 2018

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

2017 Placement Warrants Liability

 

$

—

 

 

$

—

 

 

$

7,115

 

 

$

7,115

 

2016 Placement Warrants Liability

 

 

—

 

 

 

—

 

 

 

4,729

 

 

 

4,729

 

    Total

 

$

—

 

 

$

—

 

 

$

11,844

 

 

$

11,844

 

 

The following table sets forth a summary of the changes in fair value of the Company’s Level 3 financial liabilities (in thousands):

 

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

Fair value, beginning of period

 

$

11,844

 

 

$

22,420

 

Change in fair value of Level 3 financial liabilities

 

 

(4,674

)

 

 

(116

)

Fair value of 2016 Placement Warrants at exercise

 

 

(3,458

)

 

 

(342

)

Fair value of 2017 Placement Warrants at exercise

 

 

(518

)

 

 

—

 

Fair value, end of period

 

$

3,194

 

 

$

21,962

 

 

12

 

5.

Debt

SVB Term Loan

In December 2018, the Company entered into a term loan agreement, or the SVB Term Loan, with Silicon Valley Bank, for a principal amount of $56.0 million. The SVB Term Loan has a maturity date of December 1, 2023 and bears interest at a rate of 6.30% per annum to be paid monthly over the term of the loan. Beginning on December 1, 2020 (or June 1, 2021, if the Company achieves a trailing twelve-month revenue of at least a specified amount and elects to apply such later date), the Company will make thirty-six equal monthly payments of principal (or thirty equal payments, if the Company so elects). In addition, upon repayment of the SVB Term Loan in full, the Company will make a final payment equal to 3.15% of the original aggregate principal amount of the SVB Term Loan.

The Company used the proceeds of the SVB Term Loan and cash on hand to repay in full its outstanding obligations under its then outstanding term loan, or the CRG Term Loan, and to pay fees and expenses related thereto. The Company accounted for the termination of the CRG Term Loan as a debt extinguishment and recorded a debt extinguishment loss of $2.4 million from the difference between the net carrying amount of debt and the amount paid. The debt extinguishment loss includes $0.3 million in write-offs of unamortized debt discount and debt issuance costs associated with the CRG Term Loan.

The Company received net proceeds from the SVB Term Loan of $55.4 million after related legal and consulting fees totaling $0.6 million. Such fees are accounted for as debt discount and issuance costs and presented as a direct deduction from the carrying amount of debt on the Company’s consolidated balance sheets. Debt discount, issuance costs and the final payment are amortized or accreted as interest expense over the term of the loan using the effective interest method.

The SVB Term Loan is secured by substantially all assets of the Company, except that the collateral does not include any intellectual property held by the Company, provided, however, the collateral shall include all accounts and proceeds of such intellectual property.

The SVB Term Loan contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, dividends and other distributions and transactions with affiliates. The SVB Term Loan also contains financial covenants that require the Company to maintain a minimum cash balance in accounts maintained at Silicon Valley Bank or one of its affiliates or else comply with a liquidity ratio and/or a minimum revenue target.

The SVB Term Loan includes standard events of default, including, among other things, subject in certain cases to customary grace periods, thresholds and notice requirements, the Company’s failure to fulfill its obligations under the SVB Term Loan or the occurrence of a material adverse change in the Company's business, operations, or condition (financial or otherwise). In the event of default by the Company under the SVB Term Loan, Silicon Valley Bank would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the SVB Loan, which could harm the Company's financial condition.

The Company’s scheduled future payments on the SVB Term Loan at September 30, 2019 are as follows (in thousands):

 

Year Ended December 31,

 

 

 

 

The remainder of 2019

 

$

—

 

2020

 

 

1,555

 

2021

 

 

18,667

 

2022

 

 

18,667

 

2023

 

 

17,111

 

Total future principal payments

 

 

56,000

 

Less: unamortized debt discount

 

 

(511

)

Carrying value of long-term debt

 

 

55,489

 

Less: current portion

 

 

—

 

Long-term portion

 

$

55,489

 

 


13

 

6.

Commitments and Contingencies

Operating Leases

The Company leases office space in Oakwood Village, Ohio, Mountain View, California and Denver, Colorado under noncancelable operating lease agreements. The Company leases and occupies approximately 19,800 square feet of office space in Oakwood Village, Ohio, which expires in October 2021.

In June 2014, the Company entered into an office lease agreement to lease approximately 25,500 square feet of office space located in Mountain View, California, with an original expiration date of November 2019. In June 2018, the Company entered into an amendment to extend the term of the lease agreement through July 2025.

In April 2018, the Company entered into a lease agreement to lease approximately 24,600 square feet of additional office space located in Mountain View, California. The lease commenced in December 2018 and will expire in December 2025. The Company has the option to extend the term of the lease for a period of up to five years.

In May 2019, the Company entered into a sub-lease agreement to lease approximately 19,800 square feet of office space located in Denver, Colorado. The sub-lease commenced in June 2019 and will expire in May 2021.  

In recognition of the right-of-use assets and the related lease liabilities, with the exception of the Oakwood Village, Ohio lease, the options to extend the lease term have not been included as the Company is not reasonably certain that it will exercise any such option. At September 30, 2019, the weighted-average remaining lease term in years is 5.6 years and the weighted-average discount rate used is 7.7%.

During the three and nine months ended September 30, 2019, the Company recognized the following lease costs arising from lease transactions:  

 

 

 

Three Months Ended September 30, 2019

 

 

Nine Months Ended September 30, 2019

 

Operating lease cost

 

$

782

 

 

$

2,085

 

 

During the nine months ended September 30, 2019, the Company recognized the following cash flow transactions arising from lease transactions:

 

 

 

For the Nine Months Ended September 30, 2019

 

Cash paid for amounts included in the measurement of lease liabilities

 

$

1,742

 

Right-of-use assets obtained in exchange for new operating lease liabilities

 

 

1,647

 

 

At September 30, 2019, the future payments and interest expense for the operating leases are as follows:

 

Year Ending December 31,

 

Future Payments

 

The remainder of 2019

 

$

710

 

2020

 

 

3,148

 

2021

 

 

2,831

 

2022

 

 

2,496

 

2023

 

 

2,571

 

2024

 

 

2,604

 

Thereafter

 

 

1,924

 

Total undiscounted cash flows

 

$

16,284

 

Less: imputed interest

 

 

(3,078

)

Present value of lease liabilities

 

$

13,206

 

14

 

The rent expense for operating leases for the three and nine months ended September 30, 2018 using the accounting guidance in effect at that time was $0.5 million and $0.9 million, respectively.

At December 31, 2018, the future minimum payments for the operating leases were as follows (in thousands):

 

Year Ending December 31,

 

Future Minimum

Payments

 

2019

 

$

2,070

 

2020

 

 

2,353

 

2021

 

 

2,424

 

2022

 

 

2,496

 

2023

 

 

2,571

 

Thereafter

 

 

4,532

 

Total future minimum payments

 

$

16,446

 

Legal Proceedings

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for legal proceedings when it is probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued.

Patent Litigation

On September 10, 2019, a complaint for patent infringement was filed by Varian Medical Systems, Inc., in U.S. District Court for the Northern District of California against the Company. Captioned Varian Medical Systems, Inc., v. ViewRay, Inc., the complaint alleges that the Company infringes two related patents, U.S. Patent Nos. 8,637,841 (the “’841 Patent”) and 9,082,520 (the “’520 Patent”). The Company filed its answer on November 1, 2019. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation.

Class Action Litigation

On September 13, 2019, a class action complaint for violation of federal securities laws was filed in U.S. District Court for the Northern District of Ohio against the Company, its chief executive officer, chief science officer and former chief financial officer. Captioned Corwin v. ViewRay, Inc., et al., the complaint, purportedly brought on behalf of all purchasers of the Company’s common stock between March 15, 2019 and August 8, 2019, alleges that the Company violated federal securities laws by issuing materially false and misleading statements that failed to disclose adverse facts concerning the Company’s business, operations, and financial results. The Company believes the allegations in the complaint are without merit and intends to vigorously defend the litigation.

Given the early stage of each of the litigation matters described above, at this time we are unable to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote. However, litigation is subject to inherent uncertainties, and one or more unfavorable outcomes in any claim or litigation against us could have a material adverse effect for the period in which they are resolved and on our business generally. In addition, regardless of their merits or their ultimate outcomes, lawsuits and legal proceedings are costly, divert management attention and may materially adversely affect our reputation, even if resolved in our favor.

Purchase Commitments

At September 30, 2019, the Company had $4.9 million in outstanding firm purchase commitments.

15

 

7.

Revenue

The Company derives revenue primarily from the sale of MRIdian systems and related services as well as support and maintenance services on sold systems. Revenue is categorized as product revenue, service revenue and distribution rights revenue.

The following table presents revenue disaggregated by type and geography (in thousands):

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

U.S.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

$

6,107

 

 

$

6,187

 

 

$

28,394

 

 

$

25,775

 

Service

 

1,140

 

 

 

566

 

 

 

3,094

 

 

 

1,464

 

Total U.S. revenue

$

7,247

 

 

$

6,753

 

 

$

31,488

 

 

$

27,239

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outside of U.S. ("OUS")

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

$

12,589

 

 

$

10,305

 

 

$

37,081

 

 

$

31,462

 

Service

 

908

 

 

 

490

 

 

 

2,388

 

 

 

1,242

 

Distribution rights

 

118

 

 

 

118

 

 

 

356

 

 

 

356

 

Total OUS revenue

$

13,615

 

 

$

10,913

 

 

$

39,825

 

 

$

33,060

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

$

18,696

 

 

$

16,492

 

 

$

65,475

 

 

$

57,237

 

Service

 

2,048

 

 

 

1,056

 

 

 

5,482

 

 

 

2,706

 

Distribution rights

 

118

 

 

 

118

 

 

 

356

 

 

 

356

 

Total revenue

$

20,862

 

 

$

17,666

 

 

$

71,313

 

 

$

60,299

 

 

Product Revenue

Beginning in the second quarter of 2019, the Company determined that the MRIdian system and installation of the MRIdian system, which had previously been one performance obligation, are now two performance obligations as they are capable of being distinct and are distinct within the context of the system contracts. This change occurred due primarily to changes in facts and circumstances, whereby there are now readily available resources outside the Company that can perform the system installations.

Additionally, certain revenue contracts have terms that result in the control of the system transferring to the customer upon delivery and inspection, as opposed to historically upon customer acceptance. For contracts in which control of the system transfers upon delivery and inspection, the Company recognizes revenue for the systems at the point in time when delivery and inspection by the customer has occurred. For these same contracts, the Company recognizes installation revenue over the period of installation as the installation services are performed and control is transferred to the customer. For all contracts in which control continues to transfer upon post-implementation customer acceptance, revenue for the system and installation will continue to be recognized upon customer acceptance.

Certain customer contracts with distributors do not require ViewRay installation at the ultimate user site, and the distributors may either perform the installation themselves or hire another party to perform the installation. For sales of MRIdian systems for which the Company is not responsible for installation, revenue recognition occurs when the entire system is delivered and inspected, which is when the control of the system is transferred to the customer.

 

Distribution agreement

In connection with the distribution agreement entered into in December 2014, between the Company and Itochu Corporation, or Itochu, the Company received a distribution fee of $4.0 million in three installments from Itochu for serving as the Company’s exclusive distributor for the sale and delivery of its MRIdian systems within Japan. In August 2016, the Company started recognizing distribution rights revenue ratably over the remaining term of the exclusive distribution agreement of approximately 8.5 years. A time-elapsed method is used to measure progress because control is transferred evenly over the remaining contractual period. The distribution rights revenues were $0.1 million for each of the three months ended September 30, 2019 and 2018, and $0.4 million for each of the nine months ended September 30, 2019 and 2018, respectively.

 

Contract Balances

The timing of revenue recognition, billings and cash collections results in short-term and long-term trade receivables, customer deposits, deferred revenues and deferred cost of revenue on the condensed consolidated balance sheets.

16

 

Trade receivables are recorded at the original invoiced amount, net of an estimated allowance for doubtful accounts. Trade credit is generally extended on a short-term basis. The Company occasionally provides for long-term trade credit for its maintenance services so that the period between when the services are rendered to its customers and when the customers pay for that service is within one year. Thus, the Company’s trade receivables do not bear interest or contain a significant financing component. Long-term trade receivables of $0.2 million and $0.4 million were reported within other assets in the condensed consolidated balance sheets at September 30, 2019 and at December 31, 2018, respectively. These amounts are billed in accordance with the terms of the customer contracts to which they relate and are expected to be collected three to four years from the date of invoice as the underlying maintenance services are rendered. At times, billing occurs subsequent to revenue recognition, resulting in an unbilled receivable which represents a contract asset. This contract asset is recorded as an unbilled receivable and reported as part of accounts receivable on the condensed consolidated balance sheets.

Trade receivables are periodically evaluated for collectability based on past credit history of the respective customers and their current financial condition. Changes in the estimated collectability of trade receivables are included in the results of operations for the period in which the estimate is revised. Trade receivables that are deemed uncollectible are offset against the allowance for doubtful accounts. The Company generally does not require collateral for trade receivables. There were no allowances for doubtful accounts recorded at September 30, 2019 or December 31, 2018.

Customer deposits represent payments received in advance of system installation. For domestic and international sales, advance payments received prior to inventory shipments are recorded as customer deposits. Advance payments are subsequently reclassified to deferred revenue upon inventory shipment. All customer deposits, including those that are expected to be a deposit for more than one year, are classified as current liabilities based on consideration of the Company’s normal operating cycle (the time between acquisition of the inventory components and the final cash collection from customers on these inventory components) which is in excess of one year.

Deferred revenue consists of deferred product revenue and deferred service revenue. Deferred product revenue arises from timing differences between the fulfillment of contract obligations and satisfaction of all revenue recognition criteria consistent with the Company’s revenue recognition policy. Deferred service revenue results from the advance billing for services to be delivered over a period of time. Deferred revenues expected to be realized within one year or normal operating cycle are classified as current liabilities.

Deferred cost of revenue consists of cost for inventory items that have been shipped, but revenue recognition has not yet occurred. Deferred cost of revenue is included as part of current assets as the corresponding deferred product revenue is expected to be realized within one year or the Company’s normal operating cycle.

During the three and nine months ended September 30, 2019, the Company recognized $2.4 million and $11.9 million, respectively, of revenues that were included in the deferred revenue balance at the beginning of each reporting period. During the three and nine months ended September 30, 2018, the Company recognized $12.2 million and $18.3 million, respectively, of revenues that were included in the deferred revenue balance at the beginning of each reporting period.

 

Variable Consideration

The Company records revenue from customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company estimates the transaction price at contract inception, including any variable consideration, and updates the estimate each reporting period for any changes. For the three and nine months ended September 30, 2019 the Company recognized $0.0 million and $0.9 million, respectively, in revenue from performance obligations satisfied in a prior period. The cumulative catch-up adjustment resulted from a change in transaction price related to variable consideration that was constrained in prior periods.

8.

Equity Financing

Public Offering of Common Stock

On August 14, 2018, the Company entered into an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of several underwriters, or the “Underwriters”, in connection with the issuance and sale of 16,216,217 shares of the Company’s common stock at a public offering price of $9.25 per share. In addition, the Company granted the Underwriters a 30-day option to purchase up to 2,432,432 additional shares of common stock on the same terms, which the Underwriters exercised in full. The Company completed the offering on August 17, 2018 under which it received aggregate net proceeds of approximately $161.9 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company.


17

 

Direct Registered Offerings

In February 2018, the Company entered into a securities purchase agreement pursuant to which it sold (i) 4,090,000 shares of its common stock; (ii) 3,000,581 shares of its Series A convertible preferred stock and (iii) warrants to purchase 1,418,116 shares of its common stock, or the 2018 Offering Warrants, for total gross proceeds of $59.1 million, or the March 2018 Direct Registered Offering. The March 2018 Direct Registered Offering was closed on March 5, 2018. The 2018 Offering Warrants have an exercise price of $8.31 per share, became exercisable upon issuance and expire in March 2025.

Private Placements

In September 2016, the Company completed the final closing of a private placement offering, or the 2016 Private Placement, through which it sold (i) 4,602,506 shares of its common stock and (ii) warrants that provide the warrant holders the right to purchase 1,380,745 shares of common stock, or the 2016 Placement Warrants, and raised total gross proceeds of $13.8 million. The 2016 Placement Warrants have an exercise price of $2.95 per share, are exercisable at any time at the option of the holder and expire seven years from the date of issuance.

In January 2017, the Company completed the final closing of a private placement offering, or the 2017 Private Placement, through which it sold (i) 8,602,589 shares of its common stock and (ii) warrants that provide the warrant holders the right to purchase 1,720,512 shares of its common stock, or the 2017 Placement Warrants, and raised total gross proceeds of $26.1 million. The 2017 Placement Warrants have an exercise price of $3.17 per share, became exercisable in July 2017 and expire in January 2024.

At-The-Market Offering of Common Stock

In January 2017, the Company filed a shelf registration statement on Form S-3 with the SEC, which included a base prospectus covering the offering, issuance and sale of up to a maximum aggregate offering of $75.0 million of the Company’s common stock, preferred stock, debt securities, warrants, purchase contracts and/or units. In January and April 2017, the Company agreed to sell up to a cumulative $50.0 million of its common stock in accordance with the terms of a sales agreement with FBR Capital Markets & Co., pursuant to an at-the-market offering program in accordance with Rule 415(a)(4) under the Securities Act. In January 2019, the Company filed a registration statement with the SEC which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants, purchase contracts and/or units, including up to $100.0 million of the Company’s common shares pursuant to the Company’s at-the-market offering program with FBR.

As of September 30, 2019, the Company has sold approximately $40.4 million under this at-the-market offering program. During the nine months ended September 30, 2018, the Company sold approximately $0.3 million under this at-the-market offering program.

9.

Warrants

Equity Classified Common Stock Warrants

In connection with a debt financing in December 2013, the Company issued warrants to purchase 128,231 shares of its common stock with an exercise price of $5.84 per share. These warrants were exercised during the three months ended September 30, 2019 and the Company issued 36,457 shares of its common stock upon the net exercise of the 128,231 warrants. None of these warrants remained outstanding at September 30, 2019.

In connection with the merger of the Company and ViewRay Technologies, Inc. in July 2015, or the Merger, in July and August 2015, the Company conducted a private placement offering during which the Company issued warrants, or the 2015 Placement Warrants, that provide the warrant holder the right to purchase 198,760 shares of common stock at an exercise price of $5.00 per share. The 2015 Placement Warrants are exercisable at any time at the option of the holder until the five-year anniversary of its date of issuance. Prior to September 30, 2019, the Company issued 92,487 shares of its common stock upon the net exercise of 159,010 shares of the 2015 Placement Warrants. The remaining 39,750 shares of the 2015 Placement Warrants have not been exercised and remained outstanding at September 30, 2019.

In connection with the March 2018 Direct Registered Offering, the Company issued warrants to purchase 1,418,116 shares of common stock at an exercise price of $8.31 per share, or the 2018 Offering Warrants. The 2018 Offering Warrants became exercisable upon issuance and expire in March 2025. None of the 2018 Offering Warrants have been exercised to date and they all remained outstanding at September 30, 2019.

18

 

As separate classes of securities were issued in a bundled transaction, the gross proceeds from the March 2018 Direct Registered Offering of $59.1 million was allocated to common stock, Series A convertible preferred stock and the 2018 Offering Warrants based on their respective relative fair value upon issuance. The aggregate fair value of the 2018 Offering Warrants of $7.4 million was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected term of seven years, expected volatility of 62.5%, risk-free interest rate of 2.8% and expected dividend yield of 0%. The allocated proceeds from the 2018 Offering Warrants of $6.6 million was recorded in additional paid-in-capital.

Liability Classified Common Stock Warrants

In connection with private placement offerings in 2017 and 2016, the Company issued common stock warrants, or the 2017 and 2016 Placement Warrants, which contain protection whereby the warrant holders will have the right to receive cash in the amount equal to the Black-Scholes value of the warrants upon the occurrence of a Change of Control, as defined in the 2017 and 2016 Placement Warrants. The 2017 and 2016 Placement Warrants were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date, with the change in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The key terms of the 2017 and 2016 Placement Warrants are as follows:

 

 

 

Issuance Date

 

Term

 

Exercise Price Per Share

 

 

Warrants Exercised during the Nine Months Ended September 30, 2019

 

 

Warrants Outstanding at September 30, 2019

 

2017 Placement Warrants

 

January 2017

 

7 years

 

$

3.17

 

 

 

90,642

 

 

 

1,618,890

 

2016 Placement Warrants

 

August and September 2016

 

7 years

 

$

2.95

 

 

 

593,352

 

 

 

537,263

 

   Total

 

 

 

 

 

 

 

 

 

 

683,994

 

 

 

2,156,153

 

 

During the three and nine months ended September 30, 2019, the Company recorded a gain of $13.5 million and a gain of $8.6 million, respectively, related to the change in fair value of the 2016 and 2017 Placement Warrants. During the three and nine months ended September 30, 2018, the Company recorded a loss of $6.7 million and a gain of $0.4 million, respectively, related to the change in fair value of the 2016 and 2017 Placement Warrants. The fair value of the 2016 and 2017 Placement Warrants at September 30, 2019 and December 31, 2018, respectively, was estimated using the Black-Scholes option-pricing model and the following weighted-average assumptions:

 

 

 

2017 Placement Warrants

 

 

2016 Placement Warrants

 

 

 

September 30, 2019

 

 

December 31,

2018

 

 

September 30, 2019

 

 

December 31,

2018

 

Expected term (in years)

 

 

4.3

 

 

 

5.1

 

 

3.9

 

 

 

4.7

 

Expected volatility

 

67.9%

 

 

60.8%

 

 

67.3%

 

 

60.9%

 

Risk-free interest rate

 

1.6%

 

 

2.5%

 

 

1.6%

 

 

2.5%

 

Expected dividend yield

 

0%

 

 

0%

 

 

0

 

 

0%

 

19

 

10.

Stock-Based Compensation

A summary of the Company’s stock option activity and related information is as follows:

 

 

 

 

 

 

 

Options Outstanding

 

 

 

Shares

Available

for Grant

 

 

Number

of Stock

Options

Outstanding

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual Life

(Years)

 

 

Aggregate

Intrinsic

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(In thousands)

 

Balance at December 31, 2018

 

 

1,908,626

 

 

 

11,603,708

 

 

$

6.64

 

 

 

7.6

 

 

$

10,151

 

Additional options authorized

 

 

3,853,280

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options granted

 

 

(2,624,505

)

 

 

2,624,505

 

 

 

8.19

 

 

 

 

 

 

 

 

 

Options exercised

 

 

—

 

 

 

(2,219,251

)

 

 

4.34

 

 

 

 

 

 

 

 

 

Options canceled

 

 

553,585

 

 

 

(553,585

)

 

 

6.73

 

 

 

 

 

 

 

 

 

Withheld shares to pay for taxes on RSU released shares

 

 

253,986

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSUs granted

 

 

(708,144

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RSUs canceled

 

 

70,732

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at September 30, 2019

 

 

3,307,560

 

 

 

11,455,377

 

 

$

7.58

 

 

 

7.9

 

 

$

1,011

 

Vested and exercisable at September 30, 2019

 

 

 

 

 

 

4,575,393

 

 

$

6.25

 

 

 

6.2

 

 

$

1,010

 

Vested and expected to vest at September 30, 2019

 

 

 

 

 

 

10,793,250

 

 

$

7.38

 

 

 

7.7

 

 

$

1,010

 

 

The weighted-average grant date fair value of options granted to employees were $4.71 and $5.02 per share during the nine months ended September 30, 2019 and 2018, respectively. The grant date fair values of options vested were $11.4 million and $4.3 million during the nine months ended September 30, 2019 and 2018, respectively.

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic values of options exercised were $7.8 million and $11.6 million during the nine months ended September 30, 2019 and 2018, respectively.

At September 30, 2019, total unrecognized compensation cost related to stock options granted to employees, net of estimated forfeitures, was $29.0 million which is expected to be recognized over a weighted-average period of 2.9 years.

Determination of Fair Value

The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of complex and subjective variables. The variables used to calculate the fair value of stock options using the Black-Scholes option-pricing model include actual and projected employee stock option exercise behaviors, expected price volatility of the Company’s common stock, the risk-free interest rate and expected dividends. Each of these inputs is subjective and generally requires significant judgment to determine.

The fair value of employee stock options is estimated at the date of grant using a Black-Scholes option-pricing model with the following weighted-average assumptions:  

 

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

Expected term (in years)

 

 

6.0

 

 

 

6.0

 

Expected volatility%

 

60.7%

 

 

60.4%

 

Risk-free interest rate%

 

2.4%

 

 

2.8%

 

Expected dividend yield%

 

 

0.0%

 

 

 

0.0%

 

20

 

Restricted Stock Units

From time to time, the Company grants Restricted Stock Units, or RSUs, to its Board of Directors and certain employees for their services. The RSUs granted to board members are either fully vested upon issuance or vest over a period of time from the grant date and will be released and settled upon termination of the board member’s services or the occurrence of a change in control event. In January 2019, the Company granted RSUs to its Board of Directors as part of the director compensation program. In March 2019, the Company began granting RSUs to certain employees. These RSUs vest in equal annual installments over either two or three years from the grant date and are subject to the participants continuing service to the Company over that period. The fair value of RSUs is based on the closing market price of the Company’s common stock on the grant date.

 

 

 

RSUs

 

 

 

 

Number of Shares

 

 

Weighted Average Grant Date Fair Value

 

 

Unvested at December 31, 2018

 

 

1,736,234

 

 

$

9.65

 

 

RSUs granted

 

 

708,144

 

 

 

7.79

 

 

RSUs vested

 

 

(631,252

)

 

 

9.40

 

 

Unvested at September 30, 2019

 

 

1,813,126

 

 

$

9.13

 

 

Vested and unreleased

 

 

104,173

 

 

 

 

 

 

Outstanding at September 30, 2019

 

 

1,917,299

 

 

 

 

 

 

The total grant date fair value of RSUs awarded was $5.5 million for the nine months ended September 30, 2019. The total fair value of RSUs vested was $5.9 million for the nine months ended September 30, 2019. During the nine months ended September 30, 2019, the RSUs that vested were net share settled such that the Company withheld shares with value equivalent to the employees’ obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 0.3 million and were based on the value of the RSUs on their respective vesting dates as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to taxing authorities were $2.4 million for the nine months ended September 30, 2019 and are reflected as a financing activity within the Condensed Consolidated Statement of Cash Flows. These net share settlements reduced the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. For the nine months ended September 30, 2018, the Company granted 1.8 million shares of RSUs and recorded $1.2 million in stock-based compensation expense related to the issuance of RSUs.

As of September 30, 2019, total unrecognized stock-based compensation cost related to RSUs was $12.7 million, which is expected to be recognized over a weighted-average period of 1.9 years. As of September 30, 2019, 1,617,702 RSUs are expected to vest.

Stock-Based Compensation Expense

Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations and comprehensive loss is classified as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Research and development

 

$

377

 

 

$

511

 

 

$

1,221

 

 

$

1,061

 

Selling and marketing

 

 

368

 

 

 

234

 

 

 

980

 

 

 

555

 

General and administrative

 

 

4,165

 

 

 

6,434

 

 

 

12,168

 

 

 

8,436

 

Total stock-based compensation expense

 

$

4,910

 

 

$

7,179

 

 

$

14,369

 

 

$

10,052

 

During the three and nine months ended September 30, 2019 and 2018, there was no stock-based compensation expense capitalized as a component of inventory or recognized in cost of revenue. Stock-based compensation relating to stock-based awards granted to consultants was insignificant during the three and nine months ended September 30, 2019 and 2018.


21

 

11.

Income Tax

Due to the current operating losses, the Company recorded zero income tax expense during the nine months ended September 30, 2019 and 2018, respectively. During these periods, the Company’s activities were limited to U.S. federal and state tax jurisdictions, as it does not have any significant foreign operations. The federal and state effective tax rate before valuation allowance is approximately 24% for the nine months ended September 30, 2019.

Due to the Company’s history of cumulative losses and after considering all the available objective evidence, management concluded that it is not more likely than not that all of the Company’s net deferred tax assets will be realized. Accordingly, the Company’s deferred tax assets, which include net operating loss, or NOL, carryforwards and tax credits related primarily to research and development, continue to be subject to a valuation allowance as of September 30, 2019. The Company expects to continue to maintain a full valuation allowance until there is sufficient evidence to support recoverability of its deferred tax assets.

The Company had unrecognized tax benefits of $2.1 million and $1.6 million at September 30, 2019 and December 31, 2018, respectively. The reversal of the uncertain tax benefits would not affect the effective tax rate to the extent that the Company continues to maintain a full valuation allowance against its deferred tax assets. Unrecognized tax benefits may change during the next 12 months for items that arise in the ordinary course of business.  

Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. At September 30, 2019 and December 31, 2018, there were no accrued interest and penalties related to uncertain tax positions.  

12.

Net Loss per Share

Since the Company was in a loss position for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented, because the inclusion of all potential common shares outstanding would have an anti-dilutive effect. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented, because including them would have an anti-dilutive effect:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Series A convertible preferred stock (if converted)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

494,601

 

Options to purchase common stock

 

 

11,350,034

 

 

 

11,769,686

 

 

 

10,613,157

 

 

 

10,028,174

 

Common stock warrants

 

 

3,866,555

 

 

 

4,694,837

 

 

 

4,200,541

 

 

 

4,441,885

 

Restricted stock units

 

 

437,933

 

 

 

1,457,638

 

 

 

1,206,267

 

 

 

576,464

 

Total

 

 

15,654,522

 

 

 

17,922,161

 

 

 

16,019,965

 

 

 

15,541,124

 

13.

Related Party Transactions

In December 2004, the Company entered into a licensing agreement with the University of Florida Research Foundation, or UFRF, whereby UFRF granted the Company a worldwide exclusive license to certain of UFRF’s patents in exchange for 33,652 shares of common stock and a 1% royalty, with a minimum $0.1 million royalty payment per quarter, from sales of products developed and sold by the Company utilizing the licensed patents. Minimum royalty payments in any calendar year are credited against earned royalties for such calendar year. Royalty expenses based on 1% of net sales were $0.6 million and $0.5 million during the nine months ended September 30, 2019 and 2018, respectively, and were recorded as product cost of revenue.

22

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The interim financial statements included in this Quarterly Report on Form 10-Q and this Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2018, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, contained in the Annual Report filed with the SEC on March 15, 2019. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are subject to risks and uncertainties, including those under “Risk Factors” in this Quarterly Report and the Annual Report that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements.

Unless otherwise indicated, references in this section to “ViewRay,” “we,” “us,” “our” and “the Company” refer to ViewRay, Inc. and its consolidated subsidiary, ViewRay Technologies, Inc.

As a result of the merger of the Company and ViewRay Technologies, Inc. in July 2015, or the Merger, and the change in business and operations of the Company, a discussion of the past financial results of the Company is not pertinent, and under applicable accounting principles the historical financial results of ViewRay Technologies, Inc., the accounting acquirer, prior to the Merger are considered the historical financial results of the Company.

The following discussion highlights ViewRay’s results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on ViewRay’s unaudited condensed consolidated financial statements contained in this Quarterly Report, which we have prepared in accordance with U.S. GAAP. You should read the discussion and analysis together with such condensed consolidated financial statements and the related notes thereto.

Company Overview

We design, manufacture and market the ViewRay MRIdian®. The MRIdian is an innovative system that integrates high quality radiation therapy with simultaneous magnetic resonance imaging (MRI). There are two generations of the MRIdian: the first generation MRIdian with Cobalt-60 based radiation beams and the second generation MRIdian Linac, with more advanced linear accelerator or ‘linac’ based radiation beams.

The MRIdian combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients. MRI is a broadly used imaging tool that has the ability to clearly differentiate between types of soft tissue. In contrast, X-ray or computed tomography (CT), the most commonly used imaging technologies in radiation therapy today, are often unable to distinguish soft tissues such as the tumor and critical organs. MRIdian integrates MRI technology, radiation delivery and our proprietary software to clearly See the soft tissues, Shape the dose to accommodate for changes in anatomy and Strike the target precisely using real-time targeting throughout the treatment. The MRIdian system is Sized to fit into standard radiation therapy vaults without having to remove ceiling or walls. These capabilities allow MRIdian to deliver radiation to the tumor accurately, while reducing the radiation amount delivered to nearby healthy tissue, as compared to other radiation therapy treatments currently available. We believe this will lead to improved patient outcomes and reduced treatment-related side effects.

Both generations of the MRIdian have received 510(k) marketing clearance from the US Food and Drug Administration, or FDA, and permission to affix the CE mark.  

 

•

We received initial 510(k) marketing clearance from the FDA for our treatment planning and delivery software in January 2011.

 

•

We received 510(k) marketing clearance for MRIdian, with Cobalt-60 as the radiation source, in May 2012. We received permission to affix the CE mark to MRIdian with Cobalt-60 in November 2014, allowing MRIdian with Cobalt-60 to be sold within the European Economic Area, or EEA. In August 2016, we received regulatory approval from the Japanese Ministry of Health, Labor and Welfare to market MRIdian with Cobalt-60 in Japan. In August 2016, we also received approval from the China Food and Drug Administration to market MRIdian with Cobalt-60 in China. 

 

•

In September 2016, we received the CE mark for the MRIdian Linac (with a linear accelerator as the radiation source) in the EEA. In February 2017, we received 510(k) clearance from the FDA to market MRIdian Linac. In June 2017, we received 510(k) clearance to market RayZR™, our high-resolution beam-shaping multi-leaf collimator. We also received MRIdian Linac regulatory approval in Taiwan and Canada in August 2017, and in Israel in November 2017. In March 2018, we received regulatory approval from the Japanese Ministry of Health, Labor and Welfare to market MRIdian Linac in Japan. We are also seeking required MRIdian Linac approvals in other countries.

 

23

 

MRIdian is the first radiation therapy solution that enables simultaneous radiation treatment delivery and real-time MRI imaging of a patient’s internal anatomy.  It generates high-quality images that differentiate between the targeted tumor, surrounding soft tissue and nearby critical organs. MRIdian also records the level of radiation dose that the treatment area has received, enabling physicians to adapt the prescription between treatments, as needed. We believe this improved visualization and accurate dose recording will enable better treatment, improve patient outcomes and reduce side effects.  Key benefits to users and patients include: improved imaging and patient alignment; the ability to adapt the patient’s radiation treatments to changes while the patient is still on the treatment table, or “on-table adaptive treatment planning”; MRI-based motion management; and an accurate recording of the delivered radiation dose.  Physicians have already used MRIdian to treat a broad spectrum of radiation therapy patients with more than 45 different types of cancer, as well as patients for whom radiation therapy was previously not an option.

At September 30, 2019, six MRIdian with Cobalt-60 systems and 26 MRIdian Linac systems are in operation at 30 customers worldwide (12 in the United States and 18 outside the United States). In addition, seven MRIdian Linacs have been delivered to customers.

We currently market MRIdian through a direct sales force in North America. In the rest of the world, we market MRIdian through a hybrid model of both a direct sales force and distribution network. We market MRIdian to a broad range of worldwide customers, including university research and teaching hospitals, community hospitals, private practices, government institutions and freestanding cancer centers. As with the traditional linac market, our sales and revenue cycle vary based on the particular customer and can be lengthy, sometimes lasting up to 18 to 24 months (or more) from initial customer contact to order contract execution. Following execution of a sales contract, it generally takes nine to 15 months for a customer to customize an existing facility or construct a new vault. Upon the commencement of installation at a customer’s facility, it typically takes approximately 60 to 90 days for us to install MRIdian and perform on-site testing of the system, including the completion of acceptance test procedures.

We generated total revenue of $20.9 million and $17.7 million, and had net losses of $20.8 million and $32.9 million, during the three months ended September 30, 2019 and 2018, respectively. We generated total revenue of $71.3 million and $60.3 million, and net losses of $85.0 million and $59.7 million, during the nine months ended September 30, 2019 and 2018, respectively.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We expect our expenses will increase substantially in connection with our ongoing activities, as we:

 

•

add personnel to support our product development and commercialization efforts;

 

•

continue our research and development efforts;

 

•

seek regulatory approval for MRIdian in certain foreign countries; and

 

•

operate as a public company.

Accordingly, we may seek to fund our operations through public or private equity, debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop enhancements to and integrate new technologies into MR Image-Guided radiation therapy systems.

New Orders and Backlog

New orders are defined as the sum of gross product orders, representing MRIdian contract price, recorded in backlog during the period. Backlog is the accumulation of all orders for which revenue has not been recognized and which we consider valid. Backlog includes customer deposits or letters of credit, except when the sale is to a customer where a deposit is not deemed necessary or customary. Deposits received are recorded in a customer deposit liability account on the balance sheet. Orders may be revised or cancelled according to their terms or upon mutual agreement between the parties. Therefore, it is difficult to predict with certainty the amount of backlog that will ultimately result in revenue. The determination of backlog includes objective and subjective judgment about the likelihood of an order contract becoming revenue. We perform a quarterly review of backlog to verify that outstanding orders in backlog remain valid, and based upon this review, orders that are no longer expected to result in revenue are removed from backlog. Among other criteria to consider for a transaction to be in backlog, we must possess both an outstanding and effective written agreement for the delivery of a MRIdian signed by a customer with a minimum customer deposit or a letter of credit requirement except when the sale is to a customer where a deposit is not deemed necessary or customary (i.e. sale to a government entity, a large hospital, group of hospitals or cancer care group that has sufficient credit, sales via tender awards, or indirect channel sales that have signed contracts with end-customers). We decide whether to remove or add back an order from or to our backlog by evaluating the following criteria: changes in customer or distributor plans or financial conditions; the customer’s or distributor’s continued intent and ability to fulfill the order contract; changes to regulatory requirements; the status of regulatory approval required in the customer’s jurisdiction, if any; the length of time the order has been on our backlog; and other reasons for potential cancellation of order contracts.

During the nine months ended September 30, 2019, we received new orders for MRIdian systems and upgrade orders to replace Cobalt-60 systems totaling $97.3 million. At September 30, 2019, we had total backlog of $230.7 million.

24

 

Components of Statements of Operations

Revenue

Product Revenue. Product revenue consists of revenue recognized from sales of MRIdian systems, as well as optional components, such as additional planning workstations and body coils.

Following execution of an order contract, it generally takes nine to 15 months for a customer to customize an existing facility or construct a new vault for the purchased system. Upon the commencement of installation at a customer’s facility, it typically takes approximately 60 to 90 days to complete the installation and on-site testing of the system, including the completion of acceptance test procedures. On-site training can take up to multiple weeks and can be conducted concurrently with installation and acceptance testing. Order contracts generally include customer deposits upon execution of the agreement, and in certain cases, additional amounts due at shipment or commencement of installation, and final payment due generally upon customer acceptance.

Beginning in the second quarter of 2019, for new contracts in which control of the system transfers upon delivery and inspection, the Company recognizes revenue for the system at the point in time when delivery and inspection has occurred. For these same contracts, the Company recognizes installation revenue over a period of time as control of the installation services are transferred. For all contracts in which control continues to transfer upon post-installation customer acceptance, revenue for the system and installation will continue to be recognized upon customer acceptance. For sales of MRIdian systems for which we are not responsible for installation, revenue is recognized when the entire system is delivered, which is when the control of the system is transferred to the customer.

Service Revenue. Our contracts typically include service warranty at no additional costs for one year. In addition, we offer multi-year, post-installation maintenance and support contracts that provide various levels of service support, which enables our customers to select the level of on-going support services, including parts and labor, which they require. These post-installation contracts are for a period of one to five years and provide services ranging from on-site parts and labor, and preventative maintenance to labor only with a longer response time. We also offer technology upgrades to our MRIdian systems, when and if available, for an additional fee. Service revenue is recognized ratably over the term during which the contracted services are provided.

Distribution Rights Revenue.  In December 2014, we entered into a distribution agreement with Itochu Corporation, or Itochu, pursuant to which we appointed Itochu as our exclusive distributor for the promotion, sale and delivery of MRIdian products within Japan. As consideration for the exclusive distribution rights granted, we received $4.0 million, which was recorded as deferred revenue and since August 2016, distribution rights revenue has been recognized ratably over the remaining term of the distribution agreement, which expires in December 2024. A time-elapsed method is used to measure progress because the control is transferred evenly over the contractual period.

Cost of Revenue

Product Cost of Revenue. Product cost of revenue primarily consists of the cost of materials, installation and services associated with the manufacturing and installation of MRIdian systems, and royalty payments to the University of Florida Research Foundation. Product cost of revenue also includes lower of cost or net realizable value inventory, or LCNRV, adjustments if the carrying value of the inventory is greater than its net realizable value. There was no LCNRV charge for the nine months ended September 30, 2019 and 2018.

We expect our materials, installation and service costs to decrease as we continue to scale our operations, improve product designs and work with our third-party suppliers to lower costs. We expect to continue to lower costs as we transition to MRIdian Linac.  

Service Cost of Revenue. Service cost of revenue is comprised primarily of personnel costs, training and travel expenses to service and perform maintenance on installed MRIdian systems. Service cost of revenue also includes the costs of replacement parts under maintenance and support contracts.

Operating Expenses

Research and Development. Research and development expenses consist primarily of compensation and related costs for personnel, including stock-based compensation, employee benefits and travel expenses. Other significant research and development costs arise from third-party consulting services, laboratory supplies, research materials, medical equipment, computer equipment and licensed technology, and related depreciation and amortization. We expense research and development costs as incurred. As we continue to invest in improving MRIdian and developing new technologies, we expect our research and development expenses to increase.


25

 

Selling and Marketing. Selling and marketing expenses consist primarily of compensation and related costs for our direct sales force, sales management, and marketing and customer support personnel, and include stock-based compensation, employee benefits and travel expenses. Selling and marketing expenses also include costs related to trade shows and marketing programs. We expense selling and marketing costs as incurred. We expect selling and marketing expenses to increase in future periods as we expand our sales force and our marketing and customer support organizations and increase our participation in trade shows and marketing programs.

General and Administrative. Our general and administrative expenses consist primarily of compensation and related costs for our operations, finance, human resources, regulatory, and other administrative personnel, and include stock-based compensation, employee benefits and travel expenses. In addition, general and administrative expenses include third-party consulting, legal, audit, accounting services, quality and regulatory functions and facilities costs, and gain or loss on the disposal of property and equipment. We expect our general and administrative expenses to increase as our business grows and as we invest in the development of our MRIdian Linac.

Interest Income

Interest income consists primarily of interest income received on our cash and cash equivalents.

Interest Expense

Interest expense consists primarily of interest and amortization related to our SVB Term Loan.

Other Income (Expense), Net

Other income (expense), net consists primarily of changes in the fair value of the 2017 and 2016 Placement Warrants and foreign currency exchange gains and losses.

The outstanding 2017 and 2016 Placement Warrants are re-measured to fair value at each balance sheet date with the corresponding gain or loss from the adjustment recorded as a component of other income (expense), net.  

Results of Operations

The following tables set forth our results of operations for the periods presented:

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

 

(in thousands)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

18,696

 

 

$

16,492

 

 

$

65,475

 

 

$

57,237

 

Service

 

 

2,048

 

 

 

1,056

 

 

 

5,482

 

 

 

2,706

 

Distribution rights

 

 

118

 

 

 

118

 

 

 

356

 

 

 

356

 

Total revenue

 

 

20,862

 

 

 

17,666

 

 

 

71,313

 

 

 

60,299

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

 

18,521

 

 

 

15,199

 

 

 

63,368

 

 

 

49,564

 

Service

 

 

1,767

 

 

 

2,103

 

 

 

9,489

 

 

 

4,732

 

Total cost of revenue

 

 

20,288

 

 

 

17,302

 

 

 

72,857

 

 

 

54,296

 

Gross margin

 

 

574

 

 

 

364

 

 

 

(1,544

)

 

 

6,003

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

5,641

 

 

 

4,347

 

 

 

17,135

 

 

 

12,506

 

Selling and marketing

 

 

7,297

 

 

 

3,384

 

 

 

19,845

 

 

 

10,024

 

General and administrative

 

 

19,381

 

 

 

16,721

 

 

 

49,888

 

 

 

37,070

 

Total operating expenses:

 

 

32,319

 

 

 

24,452

 

 

 

86,868

 

 

 

59,600

 

Loss from operations

 

 

(31,745

)

 

 

(24,088

)

 

 

(88,412

)

 

 

(53,597

)

Interest income

 

 

484

 

 

 

2

 

 

 

1,391

 

 

 

6

 

Interest expense

 

 

(1,069

)

 

 

(1,974

)

 

 

(2,902

)

 

 

(5,758

)

Other income (expense), net

 

 

11,499

 

 

 

(6,792

)

 

 

4,933

 

 

 

(307

)

Loss before provision for income taxes

 

 

(20,831

)

 

 

(32,852

)

 

 

(84,990

)

 

 

(59,656

)

Provision for income taxes

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Net loss

 

$

(20,831

)

 

$

(32,852

)

 

$

(84,990

)

 

$

(59,656

)


26

 

Comparison of the Three Months Ended September 30, 2019 and 2018

Revenue

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Product

 

$

18,696

 

 

$

16,492

 

 

$

2,204

 

Service

 

 

2,048

 

 

 

1,056

 

 

 

992

 

Distribution rights

 

 

118

 

 

 

118

 

 

 

—

 

Total revenue

 

$

20,862

 

 

$

17,666

 

 

$

3,196

 

 

Total revenue during the three months ended September 30, 2019 increased by $3.2 million compared to the three months ended September 30, 2018. The increase was primarily due to a $2.2 million increase in product revenue and a $1.0 million increase in service revenue during the three months ended September 30, 2019 compared to the three months ended September 30, 2018.

Product Revenue. Product revenue increased by $2.2 million during the three months ended September 30, 2019 compared to the three months ended September 30, 2018. The increase was primarily due to the increase in average selling price related to the three MRIdian Linac systems recognized in the three months ended September 30, 2019 as compared to the three MRIdian Linac systems recognized in the three months ended September 30, 2018.

Service Revenue. Service revenue increased by $1.0 million during the three months ended September 30, 2019 compared to the three months ended September 30, 2018 due to the increase in installed base.

Distribution Rights Revenue. Distribution rights revenue remained flat, as expected based on the ratable recognition of revenue over the term of this agreement, during the three months ended September 30, 2019 compared to the three months ended September 30, 2018.

Cost of Revenue

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Product

 

$

18,521

 

 

$

15,199

 

 

$

3,322

 

Service

 

 

1,767

 

 

 

2,103

 

 

 

(336

)

Total cost of revenue

 

$

20,288

 

 

$

17,302

 

 

$

2,986

 

 

Product Cost of Revenue. Product cost of revenue increased by $3.3 million during the three months ended September 30, 2019 compared to the three months ended September 30, 2018. The increase was primarily attributable to a $1.6 million increase in installation costs and a $1.3 million increase in costs of materials in the three months ended September 30, 2019 as compared to the three months ended September 30, 2018.

Service Cost of Revenue. Service cost of revenue decreased by $0.3 million during the three months ended September 30, 2019 compared to the three months ended September 30, 2018 primarily due to a decrease in the service inventory parts consumed to service MRIdian Linac systems previously installed.

Operating Expenses

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Research and development

 

$

5,641

 

 

$

4,347

 

 

$

1,294

 

Selling and marketing

 

 

7,297

 

 

 

3,384

 

 

 

3,913

 

General and administrative

 

 

19,381

 

 

 

16,721

 

 

 

2,660

 

Total operating expenses

 

$

32,319

 

 

$

24,452

 

 

$

7,867

 

27

 

Research and Development. Research and development expenses during the three months ended September 30, 2019 increased by $1.3 million, compared to the three months ended September 30, 2018. The increase was primarily attributable to an $0.8 million increase in personnel expense related to an increase in headcount and a $0.5 million increase in facilities costs.

Selling and Marketing. Selling and marketing expenses during the three months ended September 30, 2019 increased by $3.9 million, compared to the three months ended September 30, 2018. This increase was primarily attributable to a $2.3 million increase in personnel expense related to the increase in our direct salesforce, a $0.9 million increase in travel expense from the increasing salesforce and a $0.7 million increase in marketing expense.

General and Administrative. General and administrative expenses during the three months ended September 30, 2019 increased by $2.7 million, compared to the three months ended September 30, 2018. This increase was primarily driven by a $3.2 million increase in consulting and other professional services, a $1.2 million increase in travel costs, and a $0.5 million increase in office expenses. The increases were partially offset by a $2.3 million decrease in stock-based compensation expense.

Interest Expense

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Interest expense

 

$

(1,069

)

 

$

(1,974

)

 

$

905

 

Interest expense decreased during the three months ended September 30, 2019 compared to the three months ended September 30, 2018, due to the lower interest rate of the SVB Term Loan as compared to the CRG Term Loan, which was paid off in December 2018.  

Other Income (Expense), Net

 

 

 

Three Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Other income (expense), net

 

$

11,499

 

 

$

(6,792

)

 

$

18,291

 

 

Other income (expense), net during the three months ended September 30, 2019 consisted primarily of a $11.6 million decrease in the fair value of warrant liabilities related to the 2017 and 2016 Placement Warrants as a result in the reduction of the Company’s stock price and the warrants exercised during the three months ended September 30, 2019. Other income (expense), net during the three months ended September 30, 2018 consisted primarily of a $6.7 million change in fair value of warrant liabilities related to the 2017 and 2016 Placement Warrants.

 

Comparison of the Nine Months Ended September 30, 2019 and 2018

Revenue

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Product

 

$

65,475

 

 

$

57,237

 

 

$

8,238

 

Service

 

 

5,482

 

 

 

2,706

 

 

 

2,776

 

Distribution rights

 

 

356

 

 

 

356

 

 

 

—

 

Total revenue

 

$

71,313

 

 

$

60,299

 

 

$

11,014

 

 

Total revenue during the nine months ended September 30, 2019 increased by $11.0 million compared to the nine months ended September 30, 2018. The increase was primarily due to a $8.2 million increase in product revenue and a $2.8 million increase in service revenue during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018.

Product Revenue. Product revenue increased by $8.2 million during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018. The increase was due to revenue recognized on one more MRIdian Linac system in the nine months ended September 30, 2019 as compared to the nine months ended September 30, 2018 coupled with an increased average selling price.

28

 

Service Revenue. Service revenue increased by $2.8 million during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018 due to the increase in installed base.

Distribution Rights Revenue. Distribution rights revenue remained flat, as expected based on the ratable recognition of revenue over the term of the agreement, during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018.

Cost of Revenue

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Product

 

$

63,368

 

 

$

49,564

 

 

$

13,804

 

Service

 

 

9,489

 

 

 

4,732

 

 

 

4,757

 

Total cost of revenue

 

$

72,857

 

 

$

54,296

 

 

$

18,561

 

Product Cost of Revenue. Product cost of revenue increased by $13.8 million during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018. Product cost of revenue in the nine months ended September 30, 2019 was impacted by cost of revenue recognized on one more MRIdian Linac system. The total cost of revenue in the nine months ended September 30, 2019 was also impacted by approximately $6.9 million of charges, primarily driven by higher than anticipated installation costs related to historical upgrade commitments. The $6.9 million includes $5.5 million of one-time charges and $1.4 million of expenses.

Service Cost of Revenue. Service cost of revenue increased by $4.8 million during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018 primarily due to timing of services and increase in installed base for the nine months ended September 30, 2019.

Operating Expenses

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Research and development

 

$

17,135

 

 

$

12,506

 

 

$

4,629

 

Selling and marketing

 

 

19,845

 

 

 

10,024

 

 

 

9,821

 

General and administrative

 

 

49,888

 

 

 

37,070

 

 

 

12,818

 

Total operating expenses

 

$

86,868

 

 

$

59,600

 

 

$

27,268

 

 

Research and Development. Research and development expenses during the nine months ended September 30, 2019 increased by $4.6 million, compared to the nine months ended September 30, 2018. The increase was primarily attributable to a $3.6 million increase in personnel expense related to an increase in headcount and a $1.0 million increase in facilities costs.

Selling and Marketing. Selling and marketing expenses during the nine months ended September 30, 2019 increased by $9.8 million, compared to the nine months ended September 30, 2018. This increase was primarily attributable to a $6.8 million increase in personnel expense related to the increase in our direct salesforce, a $1.7 million increase in travel expense from the aforementioned increased salesforce and a $1.1 million increase in marketing expense.

General and Administrative. General and administrative expenses during the nine months ended September 30, 2019 increased by $12.8 million, compared to the nine months ended September 30, 2018. This increase was primarily driven by a $7.1 million increase in personnel expense related to an increase in headcount, which included a $3.7 million increase in stock-based compensation expense for the increased headcount and executives hired since the third quarter of 2018. Additionally, we incurred a $4.0 million increase in consulting costs, a $1.5 million increase in travel expense from the aforementioned increase in headcount, a $1.0 million increase in various office expenses, and a $0.6 million increase in facilities cost. These increases were partially offset by a $1.3 million reduction in legal costs as there were no equity offerings during the nine months ended September 30, 2019.


29

 

Interest Expense

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Interest expense

 

$

(2,902

)

 

$

(5,758

)

 

$

2,856

 

 

Interest expense decreased during the nine months ended September 30, 2019 compared to the nine months ended September 30, 2018, due to the lower interest rate of the SVB Term Loan as compared to the CRG Term Loan, which was paid off in December 2018.  

Other Income (Expense), Net

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

2019

 

 

2018

 

 

Change

 

 

 

(in thousands)

 

Other income (expense), net

 

$

4,933

 

 

$

(307

)

 

$

5,240

 

 

Other income (expense), net during the nine months ended September 30, 2019 consisted primarily of a $4.7 million decrease in the fair value of warrant liabilities related to the 2017 and 2016 Placement Warrants as a result in the reduction of the Company’s stock price and the warrants exercised during the nine months ended September 30, 2019, and $0.9 million of income related to insurance proceeds. Other income (expense), net during the nine months ended September 30, 2018 consisted primarily of a $0.4 million change in the fair value of warrant liabilities related to the 2017 and 2016 Placement Warrants.

Liquidity and Capital Resources

Since our inception in 2004, we have incurred significant net losses and negative cash flows from operations. During the nine months ended September 30, 2019 and 2018, we had net losses of $85.0 million and $59.7 million, respectively. At September 30, 2019 and December 31, 2018, we had an accumulated deficit of $484.0 million and $399.0 million, respectively.

At September 30, 2019 and December 31, 2018, we had cash and cash equivalents of $90.8 million and $167.4 million, respectively. To date, we have financed our operations principally through offerings of our capital stock, issuances of warrants, issuances of convertible promissory notes, use of term loans and receipts of customer deposits for new orders and payments from customers for systems installed and delivered. We may, from time to time, seek to raise capital through a variety of sources, including the public equity market, private equity financing, and public or private debt. In March 2018, we issued common stock, Series A convertible preferred stock and warrants to purchase common stock in the March 2018 Direct Registered Offering for gross proceeds of $59.1 million. In May 2018, we raised additional aggregate gross proceeds of $0.3 million through our at-the-market offering program under which we sold 33,097 shares of our common stock at an average sale price of $8.41 per share. In August 2018, we raised aggregate gross proceeds of $172.5 million via a public offering, in which we sold approximately 18.6 million shares of our common stock at a price of $9.25 per share. In December 2018, we entered into the SVB Term Loan for a principal amount of $56.0 million. We used the proceeds from the SVB Term Loan and cash on hand to repay in full our obligations under the outstanding CRG Term Loan. We expect that our existing cash and cash equivalents, together with the sales of MRIdian systems will enable us to conduct our planned operations for at least the next 12 months.

In January 2019, we filed a registration statement with the SEC which covers the offering, issuance and sale of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants, purchase contracts and/or units, including up to $100.0 million of our common shares pursuant to our at-the-market offering program with FBR.

We could potentially use our available financial resources sooner than we currently expect, and we may incur additional indebtedness to meet future operating needs. Adequate additional funding may not be available to us on acceptable terms or at all. In addition, although we anticipate being able to obtain additional financing, we may be unable to do so. Our failure to raise capital as and when needed could have significant negative consequences for our business, financial condition and results of operations. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K.

The following table summarizes our cash flows for the periods presented (in thousands):

 

 

 

Nine Months Ended September 30,

 

 

 

2019

 

 

2018

 

Cash used in operating activities

 

$

(76,632

)

 

$

(77,429

)

Cash used in investing activities

 

$

(7,598

)

 

$

(2,814

)

Cash provided by financing activities

 

$

7,063

 

 

$

224,635

 

30

 

Operating Activities

We have historically experienced cash outflows as we developed MRIdian with Cobalt-60 and MRIdian Linac and expanded our business. Our primary source of cash flow from operating activities is cash receipts from customers including sales of MRIdian systems and, to a lesser extent, up-front payments from customers. Our primary uses of cash from operating activities are amounts due to vendors for purchased components and employee-related expenditures.

During the nine months ended September 30, 2019, cash used in operating activities was $76.6 million, as a result of our net loss of $85.0 million and the aggregate non-cash charges of $17.8 million. Our net operating assets and liabilities increased by $9.4 million in the nine months ended September 30, 2019. Inventory increased $10.5 million, in anticipation of upcoming shipments and installations of MRIdian systems. Customer deposits and deferred revenue decreased $14.5 million and deposits on purchased inventory decreased $3.3 million as a result of revenue recognized for the eleven units of MRIdian system sales and one unit of system upgrade partially offset by additional accrual for the units currently being installed. The net change in our operating assets and liabilities was partially offset by a decrease in accounts receivable of $3.6 million resulting from the timing of collections. Deferred costs decreased by $2.0 million mainly due to the revenue recognized in the first nine months of 2019 offset by the transfer of property and equipment from deferred cost of revenue. Accounts payable increased $1.2 million resulting from the build of inventory and the timing of payments. Accrued expense and other liabilities increased by a $4.8 million mainly due to an increase in payroll and related benefits and accrued travel costs. Non-cash charges included $14.4 million of stock-based compensation expense, $3.2 million of depreciation and amortization expense, a $4.7 million gain related to the change in fair value of the 2017 and 2016 Placement Warrants, $4.4 million for historical upgrade commitments and $0.5 million of amortization of debt discount and interest accrual related to the SVB Term Loan.

During the nine months ended September 30, 2018, cash used in operating activities was $77.4 million, as a result of our net loss of $59.7 million, a $33.0 million net change in our operating assets and liabilities, and the aggregate non-cash charges of $15.3 million. The net change in our operating assets and liabilities was primarily a result of a change in inventory, customer deposits and deferred revenue, accounts payable, accounts receivable and prepaid expenses and other assets, which was partially offset by changes in accrued expenses and other long-term liabilities, deferred cost of revenue and deposits on purchased inventory. Inventory increased $22.4 million, in anticipation of upcoming shipments and installations of MRIdian systems. Customer deposits and deferred revenue decreased $12.4 million as a result of revenue recognized for the ten units of MRIdian system sales and one unit of system upgrade partially offset by additional accrual for the units currently being installed in the first nine months of 2018. Accounts payable decreased $4.1 million resulting from the timing of payment. Accounts receivable increased by $2.4 million resulting from the timing of collections. Prepaid expenses and other assets increased $2.3 million mainly due to prepayments made for insurance premiums and deferred sales commissions. The net change in our operating assets and liabilities was partially offset by a $6.7 million increase in accrued expense and other liabilities mainly resulting from accrued tax liabilities and accrued interest for the CRG Term Loan, a $2.3 million decrease in deferred cost of revenue primarily due to the revenue recognized for MRIdian systems for the nine months ended September 30, 2018, partially offset by the shipment of additional components for MRIdian systems being installed , and a $1.5 million decrease in deposits on purchased inventory due to the receipt of inventory previously paid for as deposits. Non-cash charges included $10.1 million of stock-based compensation expense, $2.7 million of amortization of debt discount and interest accrual related to the CRG Term Loan, and $2.6 million of depreciation and amortization expense, partially offset by a $0.1 million gain related to the change in fair value of the 2017 and 2016 Placement Warrants.

Investing Activities

Cash used in investing activities during the nine months ended September 30, 2019 of $7.6 million resulted primarily from $7.5 million of capital expenditures to purchase property and equipment.

Cash used in investing activities during the nine months ended September 30, 2018 of $2.8 million resulted from capital expenditures to purchase property and equipment.

Financing Activities

During the nine months ended September 30, 2019, financing activities provided $7.1 million in cash, consisting primarily of $9.7 million from the exercise of stock options, partially offset by cash used to pay taxes related to net share settlement of equity awards of $2.4 million.

During the nine months ended September 30, 2018, financing activities provided $224.6 million in cash, consisting of $172.5 million in gross proceeds from the August 2018 Public Offering of Common Stock, $59.1 million gross proceeds from the March 2018 Direct Registered Offering, $0.3 million gross proceeds from our at-the-market offering program and $3.6 million proceeds from the exercise of stock options, partially offset by offering costs of $10.6 million for the August 2018 Public Offering of Common Stock and $0.2 million for the March 2018 Direct Registered Offering.


31

 

SVB Term Loan

In December 2018, we entered into the SVB Term Loan for a principal amount of $56.0 million. The SVB Term Loan has a maturity date of December 1, 2023 and bears interest at a rate of 6.30% per annum to be paid monthly over the term of the loan. Beginning on December 1, 2020 (or June 1, 2021, if the Company achieves a trailing twelve-month revenue of at least a specified amount and elects to apply such later date), the Company will make thirty-six equal monthly payments of principal (or thirty equal payments, if the Company so elects). In addition, upon repayment of the SVB Term Loan in full, the Company will make a final payment equal to 3.15% of the original aggregate principal amount of the SVB Term Loan. The SVB Term Loan contains customary representations and warranties and customary affirmative and negative covenants applicable to the Company and its subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness, dividends and other distributions and transactions with affiliates. The SVB Term Loan also contains financial covenants that require the Company to maintain a minimum cash balance in accounts maintained at Silicon Valley Bank or one of its affiliates or else comply with a liquidity ratio and/or a minimum revenue target.

We were in compliance with all financial covenants under the SVB Term Loan at September 30, 2019.

Off-Balance Sheet Arrangements and Contractual Obligations

We did not have any off-balance sheet arrangements as of September 30, 2019. As of December 31, 2018, we did not have any off-balance sheet arrangements except for our operating leases. Additionally, there were no material changes to our contractual obligations described in our Annual Report on Form 10-K filed with the SEC on March 15, 2019, except for the changes to operating lease obligations due to the adoption of Topic 842, Leases. See the section entitled “Notes to Condensed Consolidated Financial Statements – Note 6 – Commitments and Contingencies” in the condensed consolidated financial statements.

For our contractual obligations that are expected to have an effect on our liquidity and cash flow, see section “Notes to Condensed Consolidated Financial Statements – Note 6 – Commitments and Contingencies” in the condensed consolidated financial statements and “Note 5 – Debt” in the condensed consolidated financial statements.

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

With the exception of the adoption of Topic 842, Leases, and change in the recognition of certain revenue resulting from changes in facts and circumstances (see the section entitled “Notes to Condensed Consolidated Financial Statements – Note 2 – Summary of Significant Accounting Policies” in the condensed consolidated financial statements), there have been no significant changes to our accounting policies during the nine months ended September 30, 2019, as compared to the critical accounting policies described in our Annual Report on Form 10-K filed with the SEC on March 15, 2019. We believe that the accounting policies discussed in that Annual Report are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

JOBS Act Accounting Election

We are an “emerging growth company” within the meaning of the JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies that are not emerging growth companies.

Recently Issued and Adopted Accounting Pronouncements

We review new accounting standards to determine the expected financial impact, if any, that the adoption of each new standard will have. For the recently issued and adopted accounting standards that we believe may have an impact on our condensed consolidated financial statements, see the section entitled “Notes to Condensed Consolidated Financial Statements – Note 2 – Summary of Significant Accounting Policies” in the condensed consolidated financial statements.

 

 


32

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable to smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer, or CEO, and interim chief financial officer, or interim CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our CEO and interim CFO have concluded that as of September 30, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such required information is accumulated and communicated to our management, including our CEO and interim CFO, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Control

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the third quarter of 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

33

 

PART II—OTHER INFORMATION

 

Item 1. Legal Proceedings

Patent Litigation

On September 10, 2019, a complaint for patent infringement was filed by Varian Medical Systems, Inc., in U.S. District Court for the Northern District of California against the Company. Captioned Varian Medical Systems, Inc., v. ViewRay, Inc., the complaint alleges that the Company infringes two related patents, U.S. Patent Nos. 8,637,841 (the “’841 Patent”) and 9,082,520 (the “’520 Patent”). The Company filed its answer on November 1, 2019. We believe the allegations in the complaint are without merit and intend to vigorously defend the litigation.

Class Action Litigation

On September 13, 2019, a class action complaint for violation of federal securities laws was filed in U.S. District Court for the Northern District of Ohio against the Company, our chief executive officer, chief science officer and former chief financial officer. Captioned Corwin v. ViewRay, Inc., et al., the complaint, purportedly brought on behalf of all purchasers of our common stock between March 15, 2019 and August 8, 2019, alleges that we violated federal securities laws by issuing materially false and misleading statements that failed to disclose adverse facts concerning the Company’s business, operations, and financial results. We believe the allegations in the complaint are without merit and intend to vigorously defend the litigation.

Given the early stage of each of the litigation matters described above, at this time we are unable to reasonably estimate possible losses or form a judgment that an unfavorable outcome is either probable or remote. However, litigation is subject to inherent uncertainties, and one or more unfavorable outcomes in any claim or litigation against us could have a material adverse effect for the period in which they are resolved and on our business generally. In addition, regardless of their merits or their ultimate outcomes, lawsuits and legal proceedings are costly, divert management attention and may materially adversely affect our reputation, even if resolved in our favor.

The information under the caption “Commitments and Contingencies” in Note 6 of the unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q is incorporated herein by reference.

 

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for our fiscal year ended December 31, 2018. If any of the risks discussed in our Annual Report on Form 10-K are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable.

Item 3. Defaults Upon Senior Securities.

Not applicable.

 

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Not applicable.

34

 

Item 6. Exhibits.

 

 

Exhibit

 

 

 

Incorporated by Reference

 

Filed

Number

 

Description

 

Form

 

Exhibit

 

Date Filed

 

Herewith

 

 

 

 

 

 

 

 

 

 

 

2.1

 

Agreement and Plan of Merger and Reorganization, dated as of July 23, 2015, by and among ViewRay Inc., Acquisition Sub and ViewRay Technologies, Inc.

 

S-1/A

 

2.1

 

12/16/15

 

 

 

 

 

 

 

 

 

 

 

 

 

3.1

 

Amended and Restated Certificate of Incorporation.

 

S-1/A

 

3.1

 

12/16/15

 

 

 

 

 

 

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws of ViewRay, Inc.

 

8-K

 

3.2

 

5/10/18

 

 

 

 

 

 

 

 

 

 

 

 

 

10.1

 

Separation Agreement, dated September 30, 2019, by and between ViewRay Inc. and Ajay Bansal.

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

31.1

 

Certification of Principal Executive Officer Required under Securities Exchange Act Rule 13a-14(a) and 15d-14(a).

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

31.2

 

Certification of Principal Financial Officer under Securities Exchange Act Rule 13a-14(a) and 15d-14(a).

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

32.1

 

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 and Securities Exchange Act Rule 13a-14(b).

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101

 

 

Interactive Data Files of Financial Statements and Notes

 

 

 

 

 

 

 

X

101.INS

 

Instant Document

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.SCH

 

XBRL Taxonomy Schema Document

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.CAL

 

XBRL Taxonomy Calculation Linkbase Document

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.DEF

 

XBRL Taxonomy Definition Linkbase Document

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.LAB

 

XBRL Taxonomy Label Linkbase Document

 

 

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

 

 

101.PRE

 

XBRL Taxonomy Presentation Linkbase Document

 

 

 

 

 

 

 

X

 

_____________________

35

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

VIEWRAY, INC.

 

 

 

 

Dated: November 12, 2019

By:    

 

/s/ Scott Drake

 

Name:

 

Scott Drake

 

Title:

 

Chief Executive Officer

 

 

 

(Principal Executive Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dated: November 12, 2019

By:    

 

/s/ Brian Knaley

 

Name:

 

Brian Knaley

 

Title:

 

Senior Vice President and Interim Chief Financial Officer

 

 

 

(Principal Financial Officer)

 

36

 

ViewRay (NASDAQ:VRAY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more ViewRay Charts.
ViewRay (NASDAQ:VRAY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more ViewRay Charts.